Last $2.11 USD
Change Today -0.04 / -1.86%
Volume 410.1K
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

provectus biopharmaceutica-a (PVCT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/23/14 - $6.03
52 Week Low
05/9/13 - $0.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

provectus biopharmaceutica-a (PVCT) Related Businessweek News

No Related Businessweek News Found

provectus biopharmaceutica-a (PVCT) Details

Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, is engaged in developing pharmaceuticals for oncology and dermatology indications. The company’s product line includes PV-10, which has completed Phase II study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. It is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, the company develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, it is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products. Additionally, Provectus Biopharmaceuticals, Inc. develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of certain skin cancers. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

4 Employees
Last Reported Date: 03/13/14
Founded in 2002

provectus biopharmaceutica-a (PVCT) Top Compensated Officers

Chairman, Chief Executive Officer, Chief Exec...
Total Annual Compensation: $1.1M
President, Director, President of Xantech and...
Total Annual Compensation: $1.1M
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $1.1M
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $1.1M
Compensation as of Fiscal Year 2012.

provectus biopharmaceutica-a (PVCT) Key Developments

Provectus Biopharmaceuticals, Inc. Appoints Joseph M. Chalil to its Strategic Advisory Board

Provectus Biopharmaceuticals, Inc. has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, to its Strategic Advisory Board. Dr. Chalil is Associate Director, Health Science Executives of Boehringer Ingelheim. In addition to his responsibilities at Boehringer Ingelheim, Dr. Chalil is the Co-Chair for the Industry Physician Committee of the American Association of Physicians of Indian Origin (AAPI) and has served as Scientific Advisor to AAPI for the past three years.

Provectus Biopharmaceuticals, Inc. Provides PV-10 Path to Initial Approval in U.S. Now Clear Per FDA Meeting Minutes

Provectus Biopharmaceuticals, Inc. announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013. The purpose of the meeting was to determine which of the available paths that Provectus's novel investigational oncology drug PV-10 will take in pursuit of initial FDA approval and commercialization. PV-10, a 10% solution of rose bengal disodium, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, while inducing a secondary tumor-specific immune response. As a result of this meeting, Provectus will submit data from its Phase 2 study in a formal breakthrough therapy designation (BTD) request this quarter, and should receive a decision within 60 days of receipt of that request. With the passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) in July 2012, the Food and Drug Administration (FDA) was given powerful expedited tools to speed patient access to innovative medicines for serious or life-threatening conditions (Food and Drug Administration Safety and Innovation Act (FDASIA)). FDASIA initiatives such as breakthrough therapy designation are designed to accelerate approval for new drugs that show preliminary clinical evidence of a large treatment effect. A key feature of BTD authorizes the Agency to take steps to ensure that the design of the clinical trials are as efficient as practicable, when scientifically appropriate, such as by minimizing the number of patients exposed to a potentially less efficacious treatment. Requests for BTD are reviewed and granted or rejected within 60 days of receipt. As Provectus has previously reported, based on rapid tumor destruction in a positive Phase 2 trial in melanoma patients receiving PV-10 (protocol PV-10-MM-02), input from the Agency regarding the current development plan was sought. Agency guidance (Frequently Asked Questions: Breakthrough Therapies) encourages sponsors to seek such advice prior to formal request for designation.

Provectus Pharmaceutical Inc will Change its Name to Provectus Biopharmaceuticals, Inc

Effective January 23, 2014, Provectus Pharmaceutical Inc will change its name to Provectus Biopharmaceuticals, Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PVCT:US $2.11 USD -0.04

PVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PVCT.
View Industry Companies

Industry Analysis


Industry Average

Valuation PVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 51.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROVECTUS BIOPHARMACEUTICA-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at